21st Feb 2014 09:35
LONDON (Alliance News) - Electrical Geodesics Inc said Friday that it has received clearance from the US Food and Drug Administration for its GES 400 EEG systems.
The approval means that the Geodesic 400 platform is now cleared for sale and use in clinical settings in the US market.
Electrical Geodesics said the latest approval adds three systems to its established product line and is aimed at filling the needs of a broad range of research and clinical customers, from entry level EEG through to the most advanced, dense array EEG imaging.
The new technology is based on EG's ADAPT amplifier technology platform, designed to allow faster flow of information, increased bandwidth and better networking.
The CE Marked GES 400 systems have been available for research use since mid-2013 and for clinical use in Europe and other territories under that registration. The firm said, "This clearance from the FDA allows EGI to market these powerful monitoring devices to hospitals and clinics in the large US market."
Shares in Electrical Geodesics were untraded at 136.5 pence Friday morning.
By Alice Attwood; [email protected]; @AliceAtAlliance
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
EGI.L